NO20030034L - A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes - Google Patents

A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes

Info

Publication number
NO20030034L
NO20030034L NO20030034A NO20030034A NO20030034L NO 20030034 L NO20030034 L NO 20030034L NO 20030034 A NO20030034 A NO 20030034A NO 20030034 A NO20030034 A NO 20030034A NO 20030034 L NO20030034 L NO 20030034L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
NO20030034A
Other languages
Norwegian (no)
Other versions
NO20030034D0 (en
Inventor
Paul D Van Poelje
Mark D Erion
Toshihiko Fujiwara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20030034D0 publication Critical patent/NO20030034D0/en
Publication of NO20030034L publication Critical patent/NO20030034L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
NO20030034A 2000-07-06 2003-01-03 A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes NO20030034L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
NO20030034D0 NO20030034D0 (en) 2003-01-03
NO20030034L true NO20030034L (en) 2003-03-05

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030034A NO20030034L (en) 2000-07-06 2003-01-03 A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN101301294A (en)
AU (2) AU2001273271B2 (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU761267C (en) 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ATE350385T1 (en) 2000-03-08 2007-01-15 Metabasis Therapeutics Inc NEW ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS
DE60230818D1 (en) 2001-09-24 2009-02-26 Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY
EP2329839B1 (en) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification of feeding behavior by GLP-1 and PYY
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PT1700856E (en) 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Thiazole derivative
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
EP1857118A1 (en) * 2004-12-13 2007-11-21 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
UY35065A (en) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6110903A (en) * 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
AU761267C (en) * 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
DE69926400T2 (en) * 1998-12-24 2006-05-24 Metabasis Therapeutics Inc., San Diego COMPOSITION CONTAINING INSULIN-SENSITIVE ACTIVE SUBSTANCES AND INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE) FOR THE TREATMENT OF DIABETES
DK1248604T4 (en) * 2000-01-21 2012-05-21 Novartis Ag Combinations containing dipeptidyl peptidase IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
RU2328308C2 (en) 2008-07-10
SK62003A3 (en) 2003-09-11
KR20030031952A (en) 2003-04-23
EP1372660A2 (en) 2004-01-02
NO20030034D0 (en) 2003-01-03
IL153513A0 (en) 2003-07-06
MXPA02012713A (en) 2004-09-10
WO2002003978A3 (en) 2003-10-16
AU2001273271B2 (en) 2006-01-05
WO2002003978A2 (en) 2002-01-17
BR0112212A (en) 2003-12-30
AU7327101A (en) 2002-01-21
CN100396283C (en) 2008-06-25
KR100854851B1 (en) 2008-08-27
CZ20035A3 (en) 2003-05-14
CN101301294A (en) 2008-11-12
IL153513A (en) 2014-07-31
HUP0301830A3 (en) 2007-10-29
HUP0301830A2 (en) 2003-11-28
CA2412142A1 (en) 2002-01-17
JP2004508297A (en) 2004-03-18
ZA200300044B (en) 2004-05-06
CN1599612A (en) 2005-03-23
NZ523227A (en) 2005-04-29
PL365779A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
NO20030034D0 (en) A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes
NO20042147L (en) Heterocyclic compounds and processes for their use
IS6700A (en) CETP inhibitor and atorvastatin treatment mixtures
NO20032668L (en) Gyrase Inhibitors and Uses thereof
NO20022656D0 (en) Caspase Inhibitors and Their Use
CY2008010I1 (en) COMPOUNDS INCLUDING DIPEPTYDYLOPEPTIDASE-IV INHIBITORS AND ANTI-DIABETIC AGENTS
NO20020343D0 (en) Caspase inhibitors and their use
NO20042229L (en) Type 4 phosphodiate stem inhibitors and their use
NO20016314D0 (en) Mixtures and Processes for Oilfield Applications
DK1251848T3 (en) Gyrase Inhibitors and Their Use
NO20011114D0 (en) Procedure and arrangement for fracture / gravel packs
IS6934A (en) New spirotycyclic derivatives and their use as phosphodiesterase-7 inhibitors
NO20022086D0 (en) Antidiabetic formulation and method
DK1339292T3 (en) Composition and method
PL374598A1 (en) Caspase inhibitors and uses thereof
EP1448218A4 (en) Beta-secretase inhibitors and methods of use
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
DK1322597T3 (en) Process and intermediate
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
EP1337255A4 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
IS7275A (en) Composition for the catheter and its use
DE60106740D1 (en) HYDRAZIDE AND ALKOXYAMID ANGIOGENESE INHIBITORS
NO20026065D0 (en) Processes for measuring dinophysistoxin and yessotoxin
NO20032821D0 (en) Sea-trosy and related practices

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application